Serum bile acid levels in 61 patients receiving daily doses of rifampicin and isoniazid for the treatment of tuberculosis have been investigated. Bile acids were measured using 3a-hydroxysteroid dehydrogenase in a continuous-flow system. Abnormally elevated levels were found in 44 patients (72%) during the period of study up to 80 days after onset of treatment. The results showed a mean of 24·9 umol/l and a positively skewed distribution. Whilst marginally raised levels of bilirubin were seen in some samples (mean 8·2 umol/l), these did not reflect the marked changes observed in bile acids. Patients receiving rifampicin and isoniazid may therefore have markedly elevated levels of total serum bile acids, while other tests used to assess liver function can remain normal.
Biochemical assessment of changes in liver function is often required to monitor the effects of hepatotoxic drugs. Measurement of serum bile acids may be regarded as a sensitive test of liver function, 1 and serum bile acid determination could therefore be applied in such situations.
An effective regime for treatment of tuberculosis includes the combination of isoniazid and rifampicin. Both drugs have been shown to have hepatotoxic effects. Isoniazid has been associated with a small incidence of severe hepatotoxicity2. 3 and more commonly can give transient increases in transaminase levels. Scharer and Smith showed that 10% of patients receiving isoniazid had elevations of aspartate and alanine transminase during the first 2 months of treatment." Evidence for the occurence of severe liver damage due to rifampicin is equivocal. Transient changes in liver function tests have been reported in studies where rifampicin has been used alone. Rifampicin can produce rises in bilirubin.' and also give increases in transaminase levels." Recently Galeazzi, Lorenzini and Orlandi have shown levels of serum bile acids rising in individuals given a single dose of rifampicin."
The effect on total serum bile acid levels of continued daily treatment with drug regimes which include rifampicin and isoniazid is described in this paper.
Patients and methods
In-patients at the chest wards of East Birmingham Hospital, receiving treatment for tuberculosis, were investigated in this study. Sixty-one patients (34 men and 27 women) with an age range of 15-58 years were examined over a period of 15 months. Patients with clinical evidence of liver disease were excluded from the study. All patients received daily treatment with rifampicin and isoniazid given as single doses before breakfast. Isoniazid was given as a standard 300 mg/day dose, while 450 mg/day or 600 mg/day of rifampicin was given depending on body weight. During the treatment, patients were investigated at regular intervals and samples were taken between 3 and 4 hours after the drugs were administered. In 22 patients, it was possible to obtain a blood sample for investigation before drug therapy commenced.
Total serum bile acids were determined by the method of Mashige et al.H where the 3a-hydroxyl group on the bile acid nuclei is oxidised using the enzyme 3a-hydroxysteroid dehydrogenase. The reactions shown in Figure  1 were incorporated into a modified analyser system shown in Figure 2 . Fluorescence was measured using an Aminco-Bowman spectrofluorimeter with excitation and emission wavelengths of 565 nm and 580 nm respectively, and using the following reagents: Resazurin (Kochlight, Colnbrook), 50 umol/l in Tris-HCl buffer (0·1 mol/I, pH 9·5 at 20°C) prepared directly before each analytical run. Aqueous taurocholic acid standards 0 to 60 umol/l were prepared using sodium taurocholate (Sigma).
Results for within-batch and between-batch precision are given in Table 1 . To establish the reference range for the method used, the fasting and 2-hour postprandial levels of total serum bile acids were measured in 50 healthy volunteers. These gave a mean of 4·6 umol/l with a standard deviation of 2·3 umol/l for the fasting levels, and a mean of 6·9 umol/l, with a standard deviation of 3·2 umol/l for the 2-hour postprandial levels. The patients' samples in this study were taken postprandially and an upper limit of normal was taken as 13 umol/l.
Total bilirubin estimation was based on the method of Jendrassick and Grof,9 aspartate transaminase on that of Henry et at. III 3a-Hydroxysteroid dehydrogenase (3aHSD}-Diaphorase-Na.D" reagent. One vial of 3aRRA (Nyegaard, UK) containing 3a-HSD 0·525 U* and NAD+ was dissolved in 15 ml Tris-HCl buffer (0,05 mol/l, pH 9·5 at 20°C), together with Diaphorase (Sigma) 37·5 Ut and 25 mg NAD+ (Sigma). This reagent was prepared directly before use. 
Results
The pretreatment sample results in 22 patients are shown in Table 2 . The mean, range and standard deviation for total serum bile acids are similar to the reference ranges defined in healthy volunteers. Serum bilirubin values were all within normal limits, while aspartate transaminase was raised in five patients and alkaline phosphatase in four patients. During drug treatment, 205 blood samples from the 61 patients were analysed and the following results observed. The range of total serum bile acids was 1-410 I!moVI with a mean value of 24·9 I!moVI. Markedly raised values of serum bile acids were found on one or more occasions in 44 patients (72%). Elevated levels of total serum bile acids have been observed over the first 80 days of treatment as shown in Figure 3 . No clear trends in the timing of the highest recorded levels of total serum bile acids were observed. Bilirubin levels showed a range of 1-27 I!moVI and mean of 8·2 I!moVI and all except four patients had levels within the reference range. The relationship between total serum bile acid and serum bilirubin levels in treatment samples is presented in Figure 4 . It can be seen from this figure that in most cases samples with high levels of total serum bile acids were found to have normal bilirubin levels, while on every occasion where the bilirubin level was increased total serum bile acid levels were also raised.
The relationship between total serum bile acids and alkaline phosphatase and aspartate transaminase are presented in Figures 5 and 6 . Increased values of alkaline phosphatase were found in 12 patients (19%) on one or more occasions (41 specimens). In 10 of these 12 patients the raised alkaline phosphatase was paralleled by high levels of bile acids in serum, 
Discussion
In treatment of tuberculosis with isoniazid and rifampicin, high levels of total serum bile acids have been observed. These are extremely high in some patients, as much as forty times above the reference range. Age, sex, and race distribution did not seem to have any effect on the increase of the total serum bile acid levels. In all patients, except four, serum bilirubin did not show elevated levels to correspond with the levels of total serum bile acids.
The results for the patients appear to fall into three main groups. In a first group of 16 patients during 80 days after antitubercular treatment commenced, there was no biochemical indication of liver dysfunction. Total serum bile acids and other tests used in this study to assess liver function remained within the reference range. In a second group of 18 patients, a strong relationship was found between an increased level of total serum bile acids and abnormal results of aspartate transaminase or alkaline phosphatase. A third important group in this study is formed by 24 patients, who at different stages of their antitubercular treatment showed increased total serum bile acid levels, in some cases extremely high, while other tests remained in the reference range.
Rifamycins including rifampicin itself can affect the uptake and transport of organic anions by the liver. Acocella, Nicolis and Tenconi'? showed that administration of rifamycin SV can lead to rises in serum bilirubin levels and increase retention times of bromosulphthalein and indocyanine green. Anwer et al. 13 have shown that rifampicin can inhibit the uptake of cholic and taurocholic acid into the isolated rat hepatocyte. Galeazzi, Lorenzini and Orlandi" found transient increases in serum bile acids and bilirubin levels in healthy and cirrhotic individuals after a single dose of rifampicin (900 mg), larger increases being found in the latter. Although these previous studies implicate rifampicin as being the likely cause of the increases in total serum bile acids shown by this work, combined effects of rifampicin and isoniazid to produce the very high levels seen cannot be disregarded.
The most interesting finding of this study is perhaps the fact that antitubercular drugs have in the remaining two patients with high alkaline phosphatase the serum bile acids were within the reference range. The aspartate transaminase activity was increased in 14 patients (23%) on one or more occasions (26 specimens); 13 of these patients also had abnormal levels of serum bile acids. One patient showed raised different effects on the serum levels of bile acids and bilirubin. The results presented offer further indirect evidence that the liver handles bilirubin and bile acids differently. It is not clear from this study whether the elevations of serum bile acids, sometimes to extremely high levels, are of any clinical relevance. It is possible that high levels of serum bile acids could be of prognostic use in assessing the risk of developing clinical cholestasis in patients treated with rifampicin and isoniazid. Cholestasis during treatment with rifampicin and isoniazid has been reported by Poupon et al. 14 in a single patient, who after 50 days of treatment developed centrilobular cholestasis.
With the increasing use of serum bile acid analysis for the routine assessment of liver function, it is important to note that patients receiving rifampicin and isoniazid can have markedly elevated levels of serum bile acids, even though other tests used to assess liver function may be normal.
